• 1
    Anderson DM, Lyman SD, Baird A et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 1990; 63:23543.
  • 2
    Akin C, Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004; 114:139; quiz 20.
  • 3
    Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 2006; 6:21830.
  • 4
    Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 2005; 167:83548.
  • 5
    Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978; 52:44752.
  • 6
    Mekori YA, Oh CK, Metcalfe DD. The role of c-Kit and its ligand, stem cell factor, in mast cell apoptosis. Int Arch Allergy Immunol 1995; 107:1368.
  • 7
    Padawer J. Mast cells: extended lifespan and lack of granule turnover under normal in vivo conditions. Exp Mol Pathol 1974; 20:26980.
  • 8
    Tkaczyk C, Okayama Y, Woolhiser MR, Hagaman DD, Gilfillan AM, Metcalfe DD. Activation of human mast cells through the high affinity IgG receptor. Mol Immunol 2002; 38:128993.
  • 9
    Woolhiser MR, Brockow K, Metcalfe DD. Activation of human mast cells by aggregated IgG through FcgammaRI: additive effects of C3a. Clin Immunol 2004; 110:17280.
  • 10
    Woolhiser MR, Okayama Y, Gilfillan AM, Metcalfe DD. IgG-dependent activation of human mast cells following up-regulation of FcgammaRI by IFN-gamma. Eur J Immunol 2001; 31:3298307.
  • 11
    Brown JM, Swindle EJ, Kushnir-Sukhov NM, Holian A, Metcalfe DD. Silica-directed mast cell activation is enhanced by scavenger receptors. Am J Respir Cell Mol Biol 2007; 36:4352.
  • 12
    Dawicki W, Marshall JS. New and emerging roles for mast cells in host defence. Curr Opin Immunol. 2006; 19:318.
  • 13
    Bischoff SC, Sellge G, Lorentz A, Sebald W, Raab R, Manns MP. IL-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci USA 1999; 96:80805.
  • 14
    Gebhardt T, Lorentz A, Detmer F et al. Growth, phenotype, and function of human intestinal mast cells are tightly regulated by transforming growth factor beta1. Gut 2005; 54:92834.
  • 15
    Royer B, Varadaradjalou S, Saas P, Guillosson JJ, Kantelip JP, Arock M. Inhibition of IgE-induced activation of human mast cells by IL-10. Clin Exp Allergy 2001; 31:694704.
  • 16
    Levi-Schaffer F, Piliponsky AM. Tryptase, a novel link between allergic inflammation and fibrosis. Trends Immunol 2003; 24:15861.
  • 17
    Gauchat JF, Henchoz S, Mazzei G et al. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 1993; 365:3403.
  • 18
    Huels C, Germann T, Goedert S et al. Co-activation of naive CD4+ T cells and bone marrow-derived mast cells results in the development of Th2 cells. Int Immunol 1995; 7:52532.
  • 19
    Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 1997; 99:14929.
  • 20
    Amin K, Janson C, Boman G, Venge P. The extracellular deposition of mast cell products is increased in hypertrophic airways smooth muscles in allergic asthma but not in nonallergic asthma. Allergy 2005; 60:12417.
  • 21
    Begueret H, Berger P, Vernejoux JM, Dubuisson L, Marthan R, Tunon-de-Lara JM. Inflammation of bronchial smooth muscle in allergic asthma. Thorax 2007; 62:815.
  • 22
    Berger P, Girodet PO, Begueret H et al. Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis. Faseb J 2003; 17:213941.
  • 23
    Brightling CE, Bradding P. The re-emergence of the mast cell as a pivotal cell in asthma pathogenesis. Curr Allergy Asthma Rep 2005; 5:1305.
  • 24
    Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346:1699705.
  • 25
    El-Shazly A, Berger P, Girodet PO et al. Fraktalkine produced by airway smooth muscle cells contributes to mast cell recruitment in asthma. J Immunol 2006; 176:18608.
  • 26
    Brightling CE, Ammit AJ, Kaur D et al. The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am J Respir Crit Care Med 2005; 171:11038.
  • 27
    Brightling CE, Kaur D, Berger P, Morgan AJ, Wardlaw AJ, Bradding P. Differential expression of CCR3 and CXCR3 by human lung and bone marrow-derived mast cells: implications for tissue mast cell migration. J Leukoc Biol 2005; 77:75966.
  • 28
    Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006; 117:127784.
  • 29
    Kaur D, Saunders R, Berger P et al. Airway Smooth Muscle and Mast Cell-derived CCL19 Mediate Airway Smooth Muscle Migration in Asthma. Am J Respir Crit Care Med 2006; 174:117988.
  • 30
    Yang W, Kaur D, Okayama Y et al. Human lung mast cells adhere to human airway smooth muscle, in part, via tumor suppressor in lung cancer-1. J Immunol 2006; 176:123843.
  • 31
    Page S, Ammit AJ, Black JL, Armour CL. Human mast cell and airway smooth muscle cell interactions: implications for asthma. Am J Physiol Lung Cell Mol Physiol 2001; 281:L131323.
  • 32
    Berger P, Compton SJ, Molimard M et al. Mast cell tryptase as a mediator of hyperresponsiveness in human isolated bronchi. Clin Exp Allergy 1999; 29:80412.
  • 33
    Berger P, N'Guyen C, Buckley M, Scotto-Gomez E, Marthan R, Tunon-de-Lara JM. Passive sensitization of human airways induces mast cell degranulation and release of tryptase. Allergy 2002; 57:5929.
  • 34
    Sekizawa K, Caughey GH, Lazarus SC, Gold WM, Nadel JA. Mast cell tryptase causes airway smooth muscle hyperresponsiveness in dogs. J Clin Invest 1989; 83:1759.
  • 35
    Krug N, Tschernig T, Erpenbeck VJ, Hohlfeld JM, Kohl J. Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 2001; 164:18413.
  • 36
    Thangam EB, Venkatesha RT, Zaidi AK et al. Airway smooth muscle cells enhance C3a-induced mast cell degranulation following cell-cell contact. FASEB J 2005; 19:798800.
  • 37
    Ali H, Panettieri RA, Jr. Anaphylatoxin C3a receptors in asthma. Respir Res 2005; 6:19.
  • 38
    Carroll NG, Mutavdzic S, James AL. Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J 2002; 19:87985.
  • 39
    Brightling CE, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID, Bradding P. Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma. Clin Exp Allergy 2003; 33:17116.
  • 40
    Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev 2004; 202:17590.
  • 41
    Bradding P, Roberts JA, Britten KM et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10:47180.
  • 42
    Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993; 147:697704.
  • 43
    Pesci A, Foresi A, Bertorelli G, Chetta A, Olivieri D. Histochemical characteristics and degranulation of mast cells in epithelium and lamina propria of bronchial biopsies from asthmatic and normal subjects. Am Rev Respir Dis 1993; 147:6849.
  • 44
    Bradding P. The role of the mast cell in asthma: a reassessment. Curr Opin Allergy Clin Immunol 2003; 3:4550.
  • 45
    Carroll NG, Mutavdzic S, James AL. Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax 2002; 57:67782.
  • 46
    Okumura S, Sagara H, Fukuda T, Saito H, Okayama Y. FcepsilonRI-mediated amphiregulin production by human mast cells increases mucin gene expression in epithelial cells. J Allergy Clin Immunol 2005; 115:2729.
  • 47
    Wang SW, Oh CK, Cho SH et al. Amphiregulin expression in human mast cells and its effect on the primary human lung fibroblasts. J Allergy Clin Immunol 2005; 115:28794.
  • 48
    Al-Muhsen SZ, Shablovsky G, Olivenstein R, Mazer B, Hamid Q. The expression of stem cell factor and c-kit receptor in human asthmatic airways. Clin Exp Allergy 2004; 34:9116.
  • 49
    Da Silva CA, Blay F, Israel-Biet D et al. Effect of glucocorticoids on stem cell factor expression in human asthmatic bronchi. Clin Exp Allergy 2006; 36:31724.
  • 50
    Campbell E, Hogaboam C, Lincoln P, Lukacs NW. Stem cell factor-induced airway hyperreactivity in allergic and normal mice. Am J Pathol 1999; 154:125965.
  • 51
    Allakhverdi Z, Comeau MR, Jessup HK et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 2007; 204:2538.
  • 52
    Fox CC, Jewell SD, Whitacre CC. Rat peritoneal mast cells present antigen to a PPD-specific T cell line. Cell Immunol 1994; 158:25364.
  • 53
    Frandji P, Mourad W, Tkaczyk C et al. IL-4 mRNA transcription is induced in mouse bone marrow-derived mast cells through an MHC class II-dependent signaling pathway. Eur J Immunol 1998; 28:8445.
  • 54
    Frandji P, Tkaczyk C, Oskeritzian C, David B, Desaymard C, Mecheri S. Exogenous and endogenous antigens are differentially presented by mast cells to CD4+T lymphocytes. Eur J Immunol 1996; 26:251728.
  • 55
    Nakae S, Suto H, Iikura M et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 2006; 176:22384.
  • 56
    Seroogy CM, Gern JE. The role of T regulatory cells in asthma. J Allergy Clin Immunol 2005; 116:9969.
  • 57
    Lu LF, Lind EF, Gondek DC et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006; 442:9971002.
  • 58
    Kalesnikoff J, Huber M, Lam V et al. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity 2001; 14:8011.
  • 59
    Cruse G, Kaur D, Yang W, Duffy SM, Brightling CE, Bradding P. Activation of human lung mast cells by monomeric immunoglobulin E. Eur Respir J 2005; 25:85863.
  • 60
    Matsuda K, Piliponsky AM, Iikura M et al. Monomeric IgE enhances human mast cell chemokine production: IL-4 augments and dexamethasone suppresses the response. J Allergy Clin Immunol 2005; 116:135763.
  • 61
    Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320:2717.
  • 62
    Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325:106771.
  • 63
    Takeda K, Hamelmann E, Joetham A et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J Exp Med 1997; 186:44954.
  • 64
    Williams CM, Galli SJ. Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med 2000; 192:45562.
  • 65
    Taube C, Wei X, Swasey CH et al. Mast cells, Fc epsilon RI, and IL-13 are required for development of airway hyperresponsiveness after aerosolized allergen exposure in the absence of adjuvant. J Immunol 2004; 172:6398406.
  • 66
    Gelfand EW. Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol 2004; 114:S135138.
  • 67
    Kawabori S, Kanai N, Tosho T. Proliferative activity of mast cells in allergic nasal mucosa. Clin Exp Allergy 1995; 25:1738.
  • 68
    Enerback L, Pipkorn U, Granerus G. Intraepithelial migration of nasal mucosal mast cells in hay fever. Int Arch Allergy Appl Immunol 1986; 80:4451.
  • 69
    Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA 1986; 83:44648.
  • 70
    Pawankar R, Ra C. Heterogeneity of mast cells and T cells in the nasal mucosa. J Allergy Clin Immunol 1996; 98:S24862.
  • 71
    Saitåo H, Okayama Y. Mast cells in allergic diseases. New York: Karger, Basel, 2005.
  • 72
    Ahn K, Takai S, Pawankar R et al. Regulation of chymase production in human mast cell progenitors. J Allergy Clin Immunol 2000; 106:3218.
  • 73
    Creticos PS, Peters SP, Adkinson NF, Jr et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med 1984; 310:162630.
  • 74
    Freeland HS, Pipkorn U, Schleimer RP et al. Leukotriene B4 as a mediator of early and late reactions to antigen in humans: the effect of systemic glucocorticoid treatment in vivo. J Allergy Clin Immunol 1989; 83:63442.
  • 75
    Proud D, Bailey GS, Naclerio RM et al. Tryptase and histamine as markers to evaluate mast cell activation during the responses to nasal challenge with allergen, cold, dry air, and hyperosmolar solutions. J Allergy Clin Immunol 1992; 89:1098110.
  • 76
    Shaw RJ, Fitzharris P, Cromwell O, Wardlaw AJ, Kay AB. Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB4 in allergic rhinitis. Allergy 1985; 40:16.
  • 77
    Baraniuk JN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 1997; 99:S76372.
  • 78
    Sanico AM, Koliatsos VE, Stanisz AM, Bienenstock J, Togias A. Neural hyperresponsiveness and nerve growth factor in allergic rhinitis. Int Arch Allergy Immunol 1999; 118:1548.
  • 79
    Sanico AM, Stanisz AM, Gleeson TD et al. Nerve growth factor expression and release in allergic inflammatory disease of the upper airways. Am J Respir Crit Care Med 2000; 161:16315.
  • 80
    Wu X, Myers AC, Goldstone AC, Togias A, Sanico AM. Localization of nerve growth factor and its receptors in the human nasal mucosa. J Allergy Clin Immunol 2006; 118:42833.
  • 81
    Leon A, Buriani A, Dal Toso R et al. Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci USA 1994; 91:373943.
  • 82
    Nilsson G, Forsberg-Nilsson K, Xiang Z, Hallbook F, Nilsson K, Metcalfe DD. Human mast cells express functional TrkA and are a source of nerve growth factor. Eur J Immunol 1997; 27:2295301.
  • 83
    Xiang Z, Nilsson G. IgE receptor-mediated release of nerve growth factor by mast cells. Clin Exp Allergy 2000; 30:137986.
  • 84
    Welker P, Grabbe J, Gibbs B, Zuberbier T, Henz BM. Nerve growth factor-beta induces mast-cell marker expression during in vitro culture of human umbilical cord blood cells. Immunology 2000; 99:41826.
  • 85
    Damsgaard TE, Olesen AB, Sorensen FB, Thestrup-Pedersen K, Schiotz PO. Mast cells and atopic dermatitis. Stereological quantification of mast cells in atopic dermatitis and normal human skin. Arch Dermatol Res 1997; 289:25660.
  • 86
    Jarvikallio A, Naukkarinen A, Harvima IT, Aalto ML, Horsmanheimo M. Quantitative analysis of tryptase- and chymase-containing mast cells in atopic dermatitis and nummular eczema. Br J Dermatol 1997; 136:8717.
  • 87
    Groneberg DA, Bester C, Grutzkau A et al. Mast cells and vasculature in atopic dermatitis – potential stimulus of neoangiogenesis. Allergy 2005; 60:907.
  • 88
    Steinhoff M, Neisius U, Ikoma A et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003; 23:617680.
  • 89
    Badertscher K, Bronnimann M, Karlen S, Braathen LR, Yawalkar N. Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis. Arch Dermatol Res 2005; 296:5036.
  • 90
    Weidinger S, Rummler L, Klopp N et al. Association study of mast cell chymase polymorphisms with atopy. Allergy 2005; 60:125661.
  • 91
    Fischer M, Harvima IT, Carvalho RF et al. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest 2006; 116:274856.
  • 92
    Jarvikallio A, Harvima IT, Naukkarinen A. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res 2003; 295:27.
  • 93
    Ansel JC, Kaynard AH, Armstrong CA, Olerud J, Bunnett N, Payan D. Skin-nervous system interactions. J Invest Dermatol 1996; 106:198204.
  • 94
    Groneberg DA, Serowka F, Peckenschneider N et al. Gene expression and regulation of nerve growth factor in atopic dermatitis mast cells and the human mast cell line-1. J Neuroimmunol 2005; 161:8792.
  • 95
    Groneberg DA, Welker P, Fischer TC et al. Down-regulation of vasoactive intestinal polypeptide receptor expression in atopic dermatitis. J Allergy Clin Immunol 2003; 111:1099105.
  • 96
    Caughey GH. Tryptase genetics and anaphylaxis. J Allergy Clin Immunol 2006; 117:14114.
  • 97
    Schwartz LB. Effector cells of anaphylaxis: mast cells and basophils. Novartis Found Symp 2004; 257:6574; discussion 74–69, 98–100, 276–85.
  • 98
    Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest 1989; 83:15515.
  • 99
    Okayama Y, Kirshenbaum AS, Metcalfe DD. Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: up-regulation by IFN-gamma. J Immunol 2000; 164:43329.
  • 100
    Genovese A, Stellato C, Patella V et al. Contrast media are incomplete secretagogues acting on human basophils and mast cells isolated from heart and lung, but not skin tissue. Int J Clin Lab Res 1996; 26:1928.
  • 101
    Marone G, Bova M, Detoraki A, Onorati AM, Rossi FW, Spadaro G. The human heart as a shock organ in anaphylaxis. Novartis Found Symp 2004; 257:13349; discussion 149–160, 276–185.
  • 102
    Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 2000; 80:16699.
  • 103
    Cauwels A, Janssen B, Buys E, Sips P, Brouckaert P. Anaphylactic shock depends on PI3 K and eNOS-derived NO. J Clin Invest 2006; 116:224451.
  • 104
    Nagata H, Worobec AS, Oh CK et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92:105604.
  • 105
    Donlon MA. Role of mast cell mediators in radiation injury and protection. Pharmacol Ther 1988; 39:3737.
  • 106
    Donlon MA, Walden TL, Jr. Release of biological mediators in response to acute radiation injury. Fund Appl Toxicol 1988; 11:5723.
  • 107
    Warren S, Bowers JZ. The acute radiation syndrome in man. Ann Intern Med 1950; 32:20716.
  • 108
    Soule BP, Brown JM, Kushnir-Sukhov NM, Simone NL, Mitchell JB, Metcalfe DD. Effects of γ-Radiation on FcɛRI and Toll-Like Receptor Mediated Mast Cell Activation. The Journal of Immunology 2007; 179(5):327686.
  • 109
    Choi IH, Shin YM, Park JS et al. Immunoglobulin E-dependent active fatal anaphylaxis in mast cell-deficient mice. J Exp Med 1998; 188:158792.
  • 110
    Strait RT, Morris SC, Yang M, Qu XW, Finkelman FD. Pathways of anaphylaxis in the mouse. J Allergy Clin Immunol 2002; 109:65868.
  • 111
    Abelson MB. Allergic diseases of the eye. Philadelphia: W.B. Saunders Co, 2001.
  • 112
    Friedlaender MH. Current concepts in ocular allergy. Ann Allergy 1991; 67:510, 13.
  • 113
    Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005; 115:11822.
  • 114
    Allansmith MR. Immunology of the external ocular tissues. J Am Optom Assoc 1990; 61:S1622.
  • 115
    Macleod JD, Anderson DF, Baddeley SM, Holgate ST, McGill JI, Roche WR. Immunolocalization of cytokines to mast cells in normal and allergic conjunctiva. Clin Exp Allergy 1997; 27:132834.
  • 116
    Church MK, McGill JI. Human ocular mast cells. Curr Opin Allergy Clin Immunol 2002; 2:41922.
  • 117
    Ahluwalia P, Anderson DF, Wilson SJ, McGill JI, Church MK. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. J Allergy Clin Immunol 2001; 108:44954.
  • 118
    Nakamura T, Ohbayashi M, Toda M, Hall DA, Horgan CM, Ono SJ. A specific CCR3 chemokine receptor antagonist inhibits both early and late phase allergic inflammation in the conjunctiva. Immunol Res 2005; 33:21321.
  • 119
    Chang TW, Shiung YY. Anti-IgE as a mast cell-stabilizing therapeutic agent. J Allergy Clin Immunol 2006; 117:120312; quiz 1213.
  • 120
    Cook EB, Stahl JL, Barney NP, Graziano FM. Mechanisms of antihistamines and mast cell stabilizers in ocular allergic inflammation. Curr Drug Targets Inflamm Allergy 2002; 1:16780.
  • 121
    Clark JD, Lin LL, Kriz RW et al. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell 1991; 65:104351.
  • 122
    Nabe T, Yamamoto M, Suga M, Kohno S. Intratracheal dosing with disodium cromoglycate inhibits late asthmatic response by attenuating eicosanoid production in guinea pigs. Eur J Pharmacol 2004; 497:97104.
  • 123
    Chong LK, Cooper E, Vardey CJ, Peachell PT. Salmeterol inhibition of mediator release from human lung mast cells by beta-adrenoceptor-dependent and independent mechanisms. Br J Pharmacol 1998; 123:100915.
  • 124
    Nials AT, Ball DI, Butchers PR et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 1994; 251:12735.
  • 125
    Weston MC, Peachell PT. Regulation of human mast cell and basophil function by cAMP. Gen Pharmacol 1998; 31:7159.
  • 126
    Barnes PJ. Effect of beta-agonists on inflammatory cells. J Allergy Clin Immunol 1999; 104:S107.
  • 127
    Howarth PH, Durham SR, Lee TH, Kay AB, Church MK, Holgate ST. Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am Rev Respir Dis 1985; 132:98692.
  • 128
    Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004; 114:52730.
  • 129
    MacGlashan D. Loss of receptors and IgE in vivo during treatment with anti-IgE antibody. J Allergy Clin Immunol 2004; 114:14724.
  • 130
    Elsner J, Escher SE, Forssmann U. Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases. Allergy 2004; 59:124358.
  • 131
    Price KS, Friend DS, Mellor EA, De Jesus N, Watts GF, Boyce JA. CC chemokine receptor 3 mobilizes to the surface of human mast cells and potentiates immunoglobulin E-dependent generation of interleukin 13. Am J Respir Cell Mol Biol 2003; 28:4207.
  • 132
    De Lucca GV. Recent developments in CCR3 antagonists. Curr Opin Drug Discov Devel 2006; 9:51624.
  • 133
    Chang WC, Nelson C, Parekh AB. Ca2+influx through CRAC channels activates cytosolic phospholipase A2, leukotriene C4 secretion, and expression of c-fos through ERK-dependent and -independent pathways in mast cells. FASEB J 2006; 20:23813.
  • 134
    Duffy SM, Lawley WJ, Conley EC, Bradding P. Resting and activation-dependent ion channels in human mast cells. J Immunol 2001; 167:426170.
  • 135
    Mark Duffy S, Berger P, Cruse G, Yang W, Bolton SJ, Bradding P. The K+ channel iKCA1 potentiates Ca2+ influx and degranulation in human lung mast cells. J Allergy Clin Immunol 2004; 114:6672.
  • 136
    Cruse G, Duffy SM, Brightling CE, Bradding P. Functional KCa3.1 K+ channels are required for human lung mast cell migration. Thorax 2006; 61:8805.
  • 137
    Duffy SM, Cruse G, Brightling CE, Bradding P. Adenosine closes the K+ channel KCa3.1 in human lung mast cells and inhibits their migration via the adenosine A2A receptor. Eur J Immunol 2007; 37:165362.
  • 138
    Kraft S, Fleming T, Billingsley JM et al. Anti-CD63 antibodies suppress IgE-dependent allergic reactions in vitro and in vivo. J Exp Med 2005; 201:38596.
  • 139
    Daeron M, Sterk AR, Hirata F, Ishizaka T. Biochemical analysis of glucocorticoid-induced inhibition of IgE-mediated histamine release from mouse mast cells. J Immunol 1982; 129:12128.
  • 140
    Fushimi T, Okayama H, Shimura S, Saitoh H, Shirato K. Dexamethasone suppresses gene expression and production of IL-13 by human mast cell line and lung mast cells. J Allergy Clin Immunol 1998; 102:13442.
  • 141
    Koranteng RD, Swindle EJ, Davis BJ et al. Differential regulation of mast cell cytokines by both dexamethasone and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580. Clin Exp Immunol 2004; 137:817.
  • 142
    Robin JL, Seldin DC, Austen KF, Lewis RA. Regulation of mediator release from mouse bone marrow-derived mast cells by glucocorticoids. J Immunol 1985; 135:271926.
  • 143
    Saitoh H, Shimura S, Fushimi T, Okayama H, Shirato K. Detection of surfactant protein-A gene transcript in the cells from pleural effusion for the diagnosis of lung adenocarcinoma. Am J Med 1997; 103:4004.
  • 144
    Da Silva CA, Kassel O, Mathieu E, Massard G, Gasser B, Frossard N. Inhibition by glucocorticoids of the interleukin-1beta-enhanced expression of the mast cell growth factor SCF. Br J Pharmacol 2002; 135:163440.
  • 145
    Finotto S, Mekori YA, Metcalfe DD. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J Clin Invest 1997; 99:17218.
  • 146
    Hiragun T, Peng Z, Beaven MA. Dexamethasone up-regulates the inhibitory adaptor protein Dok-1 and suppresses downstream activation of the mitogen-activated protein kinase pathway in antigen-stimulated RBL-2H3 mast cells. Mol Pharmacol 2005; 67:598603.
  • 147
    Hiragun T, Peng Z, Beaven MA. Cutting edge: dexamethasone negatively regulates Syk in mast cells by up-regulating SRC-like adaptor protein. J Immunol 2006; 177:204750.
  • 148
    Smith SJ, Piliponsky AM, Rosenhead F, Elchalal U, Nagler A, Levi-Schaffer F. Dexamethasone inhibits maturation, cytokine production and Fc epsilon RI expression of human cord blood-derived mast cells. Clin Exp Allergy 2002; 32:90613.
  • 149
    Guyer BJ, Shimamoto SR, Bradhurst AL, Grossbard EB, Dreskin SC, Nelson HS. Mast cell inhibitor R112 is well tolerated and affects prostaglandin D2 but not other mediators, symptoms, or nasal volumes in a nasal challenge model of allergic rhinitis. Allergy Asthma Proc 2006; 27:20813.
  • 150
    Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005; 115:7916.
  • 151
    Adcock IM, Chung KF, Caramori G, Ito K. Kinase inhibitors and airway inflammation. Eur J Pharmacol 2006; 533:11832.
  • 152
    Dominguez C, Powers DA, Tamayo N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel 2005; 8:42130.
  • 153
    Duan W, Wong WS. Targeting mitogen-activated protein kinases for asthma. Curr Drug Targets 2006; 7:6918.
  • 154
    Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005; 10:150319.
  • 155
    Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 2004; 173:150310.
  • 156
    Mellor EA, Frank N, Soler D et al. Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: functional distinction from CysLT1R. Proc Natl Acad Sci USA 2003; 100:1158993.
  • 157
    Mellor EA, Maekawa A, Austen KF, Boyce JA. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci USA 2001; 98:79649.
  • 158
    Bakker RA, Schoonus SB, Smit MJ, Timmerman H, Leurs R. Histamine H(1)-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 2001; 60:113342.
  • 159
    Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP. Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 2003; 305:121221.
  • 160
    Sommerhoff CP. Mast cell tryptases and airway remodeling. Am J Respir Crit Care Med 2001; 164:S5258.
  • 161
    Schmidlin F, Amadesi S, Dabbagh K et al. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol 2002; 169:531521.
  • 162
    Barry GD, Le GT, Fairlie DP. Agonists and antagonists of protease activated receptors (PARs). Curr Med Chem 2006; 13:24365.
  • 163
    Cairns JA. Inhibitors of mast cell tryptase beta as therapeutics for the treatment of asthma and inflammatory disorders. Pulm Pharmacol Ther 2005; 18:5566.
  • 164
    Arimura A, Yasui K, Kishino J et al. Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J Pharmacol Exp Ther 2001; 298:4119.
  • 165
    Kostenis E, Ulven T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med 2006; 12:1485.
  • 166
    Ly TW, Bacon KB. Small-molecule CRTH2 antagonists for the treatment of allergic inflammation: an overview. Expert Opin Investig Drugs 2005; 14:76973.
  • 167
    Ulven T, Kostenis E. Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation. Curr Top Med Chem 2006; 6:142744.
  • 168
    Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol 2004; 4:78799.
  • 169
    Haitchi HM, Holgate ST. New strategies in the treatment and prevention of allergic diseases. Expert Opin Investig Drugs 2004; 13:10724.